Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well alisertib works in treating patients with peripheral
T-cell non-Hodgkin lymphoma that has come back after a period of improvement or has not
responded to treatment. Alisertib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth.